Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

M. K. Mohamed, S. Ramalingam, Y. Lin, W. Gooding, Chandra Belani

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n = 199) with advanced NSCLC were treated with gefitinib (250mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P<0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. Conclusions: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.

Original languageEnglish (US)
Pages (from-to)780-785
Number of pages6
JournalAnnals of Oncology
Volume16
Issue number5
DOIs
StatePublished - May 1 2005

Fingerprint

Exanthema
Non-Small Cell Lung Carcinoma
Survival
gefitinib
Confidence Intervals
Diarrhea
Histology
Adenocarcinoma
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{bd64496a91464d1ca1f502972e67a9c3,
title = "Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer",
abstract = "Background: Gefitinib (Iressa{\circledR}) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n = 199) with advanced NSCLC were treated with gefitinib (250mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57{\%}; adenocarcinoma, 56{\%}. Results: Partial responses were noted in two patients (1{\%}) and disease stabilization in 66 (35{\%}) patients. The median survival (MS) was 5.9 months [95{\%} confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95{\%} CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P<0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. Conclusions: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.",
author = "Mohamed, {M. K.} and S. Ramalingam and Y. Lin and W. Gooding and Chandra Belani",
year = "2005",
month = "5",
day = "1",
doi = "10.1093/annonc/mdi157",
language = "English (US)",
volume = "16",
pages = "780--785",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. / Mohamed, M. K.; Ramalingam, S.; Lin, Y.; Gooding, W.; Belani, Chandra.

In: Annals of Oncology, Vol. 16, No. 5, 01.05.2005, p. 780-785.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

AU - Mohamed, M. K.

AU - Ramalingam, S.

AU - Lin, Y.

AU - Gooding, W.

AU - Belani, Chandra

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n = 199) with advanced NSCLC were treated with gefitinib (250mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P<0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. Conclusions: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.

AB - Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n = 199) with advanced NSCLC were treated with gefitinib (250mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P<0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. Conclusions: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.

UR - http://www.scopus.com/inward/record.url?scp=20044370274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044370274&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi157

DO - 10.1093/annonc/mdi157

M3 - Article

C2 - 15728108

AN - SCOPUS:20044370274

VL - 16

SP - 780

EP - 785

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -